Treatment of hyperprolactinaemia with metergoliie for periods up to 5 years: Clinical and biological tolerability

Abstract

Forty patients with hyperprolactinaemia were treated with metergoline (8 to 12 mg/day) for periods up to 5 years. Analysis of the results of clinical and biological tolerability showed that treatment was generally well tolerated and although 28 patients complained of drug-related side-effects of various kinds, principally nausea, these were usually mild, present at the beginning of treatment and disappeared spontaneously in spite of continued metergoline administration over a prolonged period. No patient stopped treatment because of side-effects. Laboratory parameters also stayed within normal levels and there was no evidence of any alterations in the ECG. It is concluded, therefore, that metergoline is a well-tolerated as well as an effective ergolinic compound for use in those patients in whom prolonged treatment with a prolactin-lowering drug is considered necessary.

Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins

“…Antagonism of 5-HT2BR has also blocked druginduced valvulopathy in rats (Droogmans et al, 2007). In line with this, many 5-HT2AR antagonists lack links to fibrosis, including lisuride (Hofmann et al, 2006;Zajdel et al, 2015) and metergoline (Falsetti et al, 1983). Some 5-HT2BR antagonists, for example, terguride, may even protect against fibrosis (Dees et al, 2011).…”